Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atai Life Sciences N.V. (NQ: ATAI )

1.849 +0.009 (+0.47%)
Streaming Delayed Price Updated: 11:45 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Atai Life Sciences N.V.

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Numinus Wellness, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
The Latest Analyst Ratings for ATAI Life Sciences
Via Benzinga
Psychedelic Stock Gainers And Losers From March 6, 2023
Via Benzinga
Atai Update: Ketamine Trials Are Ongoing, Company Cuts 30% Workforce
The clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) founded in 2018 shared updates on the two clinical trials as well as its plan to streamline its workforce with significant... 
Via Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   
Via Benzinga
Atai Layoffs 2023: What to Know About the Latest ATAI Job Cuts
Atai Life Sciences has just announced 30% job cuts. Here's how investors should be interpreting the Atai layoffs as ATAI stock rises. 
Via InvestorPlace
Atai Life Sciences: Long On Money; Short On Success
A review of Atai Life Sciences' latest quarterly financials, the history of its stock price performance, and the price forecasts for the stock over the next 12 months. 
Via Talk Markets
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From March 2, 2023
Via Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From February 28, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From February 27, 2023
Via Benzinga
"Rags-To-Riches" Portfolio Outpacing S&P 500 By 2-To-1 Margin
The 
Via Talk Markets
Of The 6 Largest Psychedelic Drug Stocks, Only One Has Not Advanced YTD
The most critical financial information on the health of a company is whether, or not, it has a Net Positive Operating Cash Flow; its Altman -Z Score; its Piotroski F-Score; and the percentage... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From February 24, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From February 23, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From February 22, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From February 21, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From February 20, 2023
Via Benzinga
"Rags-To-Riches" Portfolio Underperforming YTD
The munKNEE 
Via Talk Markets
6 Largest Psychedelic Stocks Showing Strength; Up 11.5% YTD
A look at the performance of the six largest psychedelic stocks by market capitalization. 
Via Talk Markets
ATAI Life Sciences, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From February 15, 2023
Via Benzinga
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Mind Medicine, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Major Psychedelic Compound-Based Stocks UP 13% YTD
We track the performance of the 6 largest companies researching the treatment of mental illnesses based on the use of one or more of 10 different psychedelic compound-based substances. 
Via Talk Markets
Cybin, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.